Key Highlights

  • Third-quarter Revenue reached USD 19.2 million for NewAmsterdam Pharma (NASDAQ:NAMS), up from USD 0.3 million a year earlier, and it was driven by USD 18.3 million of license revenue plus USD 0.8 million of Supply revenue.
  • The loss narrowed to USD 17.4 million, or USD 0.14 per share, from USD 72.0 million, or USD 0.61, largely because a Warrant Fair Value gain of USD 23.1 million replaced a year-earlier loss of USD 23.8 million.
  • Research and development spending increased to USD 39.4 million from USD 31.0 million, pushing total operating expenses to USD 63.4 million from USD 55.5 million and leaving an operating loss of USD 44.2 million.
  • Cash, cash equivalents and marketable securities totaled USD 643.1 million at September 30, 2026, while the interim analysis of the PREVAIL outcomes trial is scheduled for the fourth quarter of 2026.

Licensing Income Pushes Quarterly Revenue Higher

NewAmsterdam Pharma (NASDAQ:NAMS), a late-stage biopharmaceutical developer of the oral cholesterol-lowering candidate obicetrapib, filed its third-quarter report on November 4, 2026. Revenue reached USD 19.2 million, against USD 0.3 million a year earlier, and USD 18.3 million of that was license income. Across nine months, revenue came to USD 25.9 million compared with USD 22.5 million, so the quarterly leap partly reflects timing, since the prior-year nine months contained USD 22.1 million of license revenue tied to research and development. Under its Menarini agreement, the company has collected EUR 46 million in milestone payments to date, of which EUR 16 million arrived during the first nine months of 2026.

Warrant Revaluation Accounts for Most of the Narrower Loss

The loss contracted by USD 54.6 million, but the underlying drivers deserve a closer look. The swing in warrant fair value was worth USD 46.9 million, and the company now values warrants using a Black-Scholes model that relies mostly on its own share price. Higher revenue also helped. Meanwhile, spending climbed: Research and Development rose USD 8.4 million, partly because medical affairs costs were reclassified out of selling, general and administrative expenses, which edged down to USD 24.0 million. Interest income slid to USD 5.2 million from USD 6.7 million on a smaller Investment balance, and the quarter included USD 1.2 million of income tax expense for a tax year still under review. The nine-month loss was USD 130.0 million against USD 128.9 million, so the year-to-date loss has not narrowed.

European Approvals, PREVAIL Interim Review and Liquidity

The European Commission authorized Ubeslo and Evlarco for Marketing in September 2026. The company expects Menarini to begin launches in Germany by the end of 2026, while decisions in Switzerland and the United Kingdom are anticipated later this year. In the United States, the company intends to commercialize obicetrapib itself if it is approved. An independent monitoring board will conduct an interim analysis of the PREVAIL cardiovascular outcomes trial in the fourth quarter of 2026, with a recommendation expected in the first quarter of 2027. The trial could be halted early for efficacy or futility, or it could continue. RUBENS topline results are expected around year end 2026. No shares were sold under the at-the-market program during the nine months, and 2,420,632 warrants remain outstanding.

Where Things Stand

The revenue jump came from a large license payment landing in the quarter rather than from scaled product sales. NewAmsterdam Pharma (NASDAQ:NAMS) also gained from a USD 23.1 million warrant revaluation, while operating costs rose and the nine-month loss was roughly flat. The Balance Sheet is solid at USD 643.1 million. The filing offers no price move or consensus figure. Key markers are the German launch by Menarini, the PREVAIL interim recommendation expected in the first quarter of 2027 and the RUBENS topline data.